Challenges in Immunomodulation for Psoriasis: Recent Advancements and
Need of Therapies

Dilpreet      Singh

doi:10.2174/0115748855274998231113110529

Abstract

Psoriasis is a chronic immune-mediated skin disorder affecting millions worldwide. The pathogenesis of psoriasis involves dysregulated immune responses characterized by aberrant activation of T cells and proinflammatory cytokines. Immunomodulation has emerged as a promising therapeutic approach for managing psoriasis, aiming to restore immune homeostasis. However, despite significant advancements, challenges persist in developing effective immunomodulatory therapies. This abstract reviews recent developments in psoriasis immunomodulation, encompassing novel targets and therapeutic modalities. Advances in biologics targeting interleukins (IL) and their receptors, such as IL-17, IL-23, and IL-12/23, have demonstrated substantial clinical efficacy. Additionally, small molecules that inhibit Janus kinases (JAK) and phosphodiesterase 4 (PDE4) have shown promise in regulating immune responses. Despite these advancements, certain limitations hinder the success of immunomodulatory therapies. Treatment resistance, safety concerns, and high costs remain critical challenges. Furthermore, a deeper understanding of the complex immunopathogenesis of psoriasis is essential for developing targeted and personalized therapies. In conclusion, immunomodulation has revolutionized the management of psoriasis, offering remarkable improvements in patient outcomes. Continued research and innovative therapeutic strategies are needed to overcome current challenges and pave the way for more efficient, safe, and accessible treatments for psoriasis.

« Previous Next »

[1]
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet  2020; 395(10201): 1541-9.
 [PMID: 30097359]

[2]
Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet  2019; 394(10198): 576-86.
 [http://dx.doi.org/10.1016/S0140-6736(19)30952-3] [PMID: 31280967]

[3]
Gottlieb A, Burge R, Malatestinic W, et al. Achievement of the National psoriasis foundation treatment treat-to-target goals in the US Ixekizumab customer support program. SKIN The Journal of Cutaneous Medicine  2023; 7(3): s201.
 [http://dx.doi.org/10.25251/skin.7.supp.201]

[4]
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA  2020; 323(19): 1945-60.
 [http://dx.doi.org/10.1001/jama.2020.4006] [PMID: 32427307]

[5]
Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol  2011; 25(s4) (Suppl. 4): 9-14.
 [http://dx.doi.org/10.1111/j.1468-3083.2011.04060.x] [PMID: 21507078]

[6]
Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol  2007; 25(6): 535-46.
 [http://dx.doi.org/10.1016/j.clindermatol.2007.08.007] [PMID: 18021890]

[7]
Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat  2023; 34(1): 2133531.
 [http://dx.doi.org/10.1080/09546634.2022.2133531] [PMID: 36200762]

[8]
Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med  2016; 375(4): 345-56.
 [http://dx.doi.org/10.1056/NEJMoa1512711] [PMID: 27299809]

[9]
Singh JA, Guyatt G. Systematic reviews and meta-analyses for the treatment of psoriatic arthritis: A critical review. Curr Rheumatol Rep  2018; 20(5): 25.
 [PMID: 29611005]

[10]
Soleymani T, Hung T, Soung J, Theodoro MF, Rengifo-Pardo M. New and emerging systemic therapies for psoriasis. J Am Acad Dermatol  2019; 81(1): 23-32.
 [PMID: 30502415]

[11]
Warren RB, Paul C, Griffiths CEM, et al. Secukinumab provides sustained improvements in the signs and symptoms of moderate-to-severe psoriasis up to 5 years: Results from the phase 3 FIXTURE trial. Br J Dermatol  2021; 184(5): 818-29.

[12]
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized controlled trial (BE READY). J Am Acad Dermatol  2020; 83(5): 1282-93.
 [PMID: 32574587]

[13]
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med  2015; 373(14): 1318-28.
 [http://dx.doi.org/10.1056/NEJMoa1503824] [PMID: 26422722]

[14]
Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci  2023; 24(17): 13313.
 [http://dx.doi.org/10.3390/ijms241713313] [PMID: 37686119]

[15]
Singh S, Awasthi R. Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery.  J Drug Dev Sci Technol 2023; p. 104548.

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115748855274998231113110529	Print ISSN 1574-8855
Publisher Name Bentham Science Publisher	Online ISSN 2212-3903

Current Drug Therapy

Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies

Abstract Play Pause

Abstract